Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 104 entries
View as:

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05868382 Org: User:
Start: 05/15/23 End: 12/19/23 Due: 12/19/24

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03325075 Org: User:
Start: 07/19/17 End: 03/19/19 Due: 03/19/20

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT04975893 Org: User:
Start: 06/18/21 End: 12/30/26 Due: 12/30/27

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Phase: N/A Priority: Normal
NCT ID: NCT06143046 Org: User:
Start: 11/15/23 End: 02/18/26 Due: 02/18/27

A Retrospective Study to Characterize Participants With Propionic Acidemia and Methylmalonic Acidemia

Phase: N/A Priority: Normal
NCT ID: NCT05769621 Org: User:
Start: 06/16/23 End: 03/24/26 Due: 03/24/27

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05533697 Org: User:
Start: 08/18/22 End: 12/08/27 Due: 12/08/28

Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06243770 Org: User:
Start: 02/16/24 End: 07/10/25 Due: 07/10/26

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05701800 Org: User:
Start: 01/23/23 End: 06/30/26 Due: 06/30/27

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT05894525 Org: User:
Start: 11/15/22 End: 05/26/23 Due: 05/26/24

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

Phase: N/A Priority: Normal
NCT ID: NCT05095727 Org: User:
Start: 06/01/22 End: 12/26/28 Due: 12/26/29

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03014089 Org: User:
Start: 12/21/16 End: 07/31/19 Due: 07/31/20

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Phase: N/A Priority: Normal
NCT ID: NCT06133010 Org: User:
Start: 02/08/24 End: 12/14/27 Due: 12/14/28

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05894590 Org: User:
Start: 11/15/22 End: 12/20/23 Due: 12/20/24

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Phase: N/A Priority: Normal
NCT ID: NCT06033261 Org: User:
Start: 09/06/23 End: 04/25/25 Due: 04/25/26

Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia

Phase: N/A Priority: Normal
NCT ID: NCT03810690 Org: User:
Start: 05/28/19 End: 08/18/20 Due: 08/18/21

A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06655870 Org: User:
Start: 10/31/24 End: 12/20/25 Due: 12/20/26

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT05995275 Org: User:
Start: 08/15/23 End: 07/03/25 Due: 07/03/26

A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults

Phase: N/A Priority: Normal
NCT ID: NCT05366322 Org: User:
Start: 09/10/21 End: 03/21/22 Due: 03/21/23

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT06694389 Org: User:
Start: 11/18/24 End: 12/10/25 Due: 12/10/26

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04813796 Org: User:
Start: 03/11/21 End: 07/25/23 Due: 07/25/24

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT05585632 Org: User:
Start: 10/14/22 End: 02/28/24 Due: 02/28/25

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Phase: N/A Priority: Normal
NCT ID: NCT06508320 Org: User:
Start: 07/15/24 End: 09/17/25 Due: 09/17/26

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Phase: N/A Priority: Normal
NCT ID: NCT04064905 Org: User:
Start: 07/30/19 End: 03/22/21 Due: 03/22/22

Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study

Phase: N/A Priority: Normal
NCT ID: NCT04958304 Org: User:
Start: 09/01/21 End: 09/22/23 Due: 09/22/24

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT04405076 Org: User:
Start: 05/29/20 End: 10/28/21 Due: 10/28/22